Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

Eitemau Tebyg

• The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes
  gan: Inagaki, Nobuya, et al.
  Cyhoeddwyd: (2016)
• Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies
  gan: Suzuki, Shuichi, et al.
  Cyhoeddwyd: (2017)
• Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study
  gan: Miyagawa, J., et al.
  Cyhoeddwyd: (2015)
• Effect of Once-Weekly Dulaglutide on Glucose Levels in Japanese Patients with Type 2 Diabetes: Findings from a Phase 4, Randomized Controlled Trial
  gan: Inoue, Megumi, et al.
  Cyhoeddwyd: (2019)
• Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
  gan: Odawara, M., et al.
  Cyhoeddwyd: (2016)